Filing Details

Accession Number:
0000950170-24-011491
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-05 20:45:12
Reporting Period:
2024-02-01
Accepted Time:
2024-02-05 20:45:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1701108 Spero Therapeutics Inc. SPRO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1946366 Kamal Hamed C/O Spero Therapeutics, Inc.
675 Massachusetts Avenue, 14Th Floor
Cambridge MA 02139
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-01 239,731 $0.00 816,192 No 4 A Direct
Common Stock Disposition 2024-02-02 28,075 $1.37 788,117 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
  2. The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023 pursuant to a "sell to cover" provision included in the RSU Agreement.
  3. Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.